H&T Presspart, a manufacturer of components for metered dose inhalers (MDIs), has entered a collaboration with Hovione Technology to support a strategic plan to expand its portfolio of novel drug delivery systems in respiratory care. H&T Presspart has acquired the global rights to manufacture and commercialize a capsule-based dry powder inhaler (DPI) developed by Hovione. H&T Presspart released an enhanced version of the DPI, which will be marketed as PowdAir Plus.
  
PowdAir Plus is a new capsule-based DPI designed for advanced simplicity, ease of use and affordability. PowdAir Plus’ all-plastic, four-component design minimizes manufacturing assembly and production costs. 
 
Pharmaceutical companies that work with H&T Presspart on this device can also access Hovione’s API formulation and manufacturing services along with H&T Presspart’s manufacturing capabilities. 
 
“This is a strategically significant partnership for H&T Presspart and underlines our commitment to forging alliances that accelerate the development, global scale-up and commercialisation of novel drug delivery solutions for respiratory patients,” said Peter Schmelzer, chairman of H&T Presspart. “This partnership supports our strategy to respond to the rapidly growing demand for dry powder inhalers across a range of needs, with this collaboration focused on providing a solution for developing markets.”
 
“We are delighted with the collaboration with H&T Presspart. With our expertise in DPI invention, design and development and Presspart’s mastery of large scale industrialization and global distribution, we are very confident about success,” said Peter Villax, chief executive officer of Hovione Technology, a company founded by the shareholders of Hovione, a 58-year old manufacturer of Active Pharmaceutical Ingredients (APIs).